04:15 AM EDT, 07/22/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said late Monday it will voluntarily and temporarily pause all shipments of Elevidys, a Duchenne muscular dystrophy treatment, in the US, effective close of business Tuesday.

The move will help address the US Food and Drug Administration's requests for information and complete the Elevidys safety labeling supplement process, the company said.

Sarepta shares were down 7.7% in recent premarket activity Tuesday, following a 5.4% drop in the previous session.